Publications by authors named "Nicholas Thatcher"

Claim this Profile
C
Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
Nicholas Thatcher, Jerome H Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan

Clin Cancer Res· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
Nicholas Thatcher, Jerome H Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan

Clin Cancer Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilars: what the oncologist should know.
Marc Thill, Nicholas Thatcher, Vladimir Hanes, Gary H Lyman

Future Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'Dos and don'ts' in the management of hyponatremia.
Simon Aylwin, Volker Burst, Alessandro Peri, Isabelle Runkle, Nicholas Thatcher

Curr Med Res Opin· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The diagnosis and management of inpatient hyponatraemia and SIADH.
Paul Grant, John Ayuk, Pierre-Marc Bouloux, Mark Cohen, Iain Cranston, Nicholas Thatcher

Eur J Clin Invest· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Awareness and understanding of cancer immunotherapy in Europe.
Håkan Mellstedt, Gustav Gaudernack, Winald R Gerritsen, Christoph Huber, Ignacio Melero, Nicholas Thatcher

Hum Vaccin Immunother· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic vaccines for cancer: an overview of clinical trials.
Ignacio Melero, Gustav Gaudernack, Winald Gerritsen, Christoph Huber, Giorgio Parmiani, Nicholas Thatcher

Nat Rev Clin Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
Rodryg Ramlau, Vera Gorbunova, Tudor Eliade Ciuleanu, Silvia Novello, Mustafa Ozguroglu, Nicholas Thatcher

J Clin Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.
Rovel Colaco, Hamid Sheikh, Paul Lorigan, Fiona Blackhall, Paul Hulse, Nicholas Thatcher

Lung Cancer· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Beth Woods, Noman Paracha, David A Scott, Nicholas Thatcher

Lung Cancer· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.
Hamid Sheikh, Rovel Colaco, Paul Lorigan, Fiona Blackhall, Raffaele Califano, Nicholas Thatcher

Lung Cancer· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Marina Chiara Garassino, Valter Torri, Giovanni Michetti, Monica Lo Dico, Nicla La Verde, Nicholas Thatcher

Lung Cancer· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer.
Nicholas Thatcher, Jim Heighway

Oncologist· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study).
Helge G Bischoff, Ben van den Borne, Francisco L Pimentel, Jorge Arellano, Frank Langer, Nicholas Thatcher

Curr Med Res Opin· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib for the treatment of non-small-cell lung cancer.
Lynn Campbell, Fiona Blackhall, Nicholas Thatcher

Expert Opin Pharmacother· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
Neil Hawkins, David A Scott, Beth S Woods, Nicholas Thatcher

Value Health· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k.
Nicholas Thatcher, Marianne Nicolson, Richard W Groves, Jeremy Steele, Beth Eaby

Oncologist· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib or docetaxel in advanced non-small-cell lung cancer.
Michael Cullen, Nicholas Thatcher

Lancet· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.
Nicholas Thatcher

BMC Proc· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.
Sylke Nagel, Raffaele Califano, Nicholas Thatcher, Fiona Blackhall

Expert Opin Pharmacother· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving survival improvement in thoracic tumours: from therapeutic strategy management to pharmacogenomics.
Nicholas Thatcher, Christian Manegold

Lung Cancer· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The place of targeted therapy in the patient management of non-small cell lung cancer.
Nicholas Thatcher

Lung Cancer· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival improvement in thoracic cancer: progress from the last decade and beyond.
Christian Manegold, Nicholas Thatcher

Lung Cancer· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
Mary E R O'Brien, Tudor-Eliade Ciuleanu, Hristo Tsekov, Yaroslav Shparyk, Branka Cuceviá, Nicholas Thatcher

J Clin Oncol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
Richard Booton, Tim Ward, Jim Heighway, Linda Ashcroft, Julie Morris, Nicholas Thatcher

J Thorac Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis